Literature DB >> 19139838

[The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].

M Stangel1, H-P Hartung, R Gold, B C Kieseier.   

Abstract

Long-term treatment of immune-mediated polyneuropathies remains difficult. For acute polyneuritis, or Guillain-Barré syndrome, the established standard therapy utilizes high doses of polyvalent intravenous immunoglobulins (IVIG). A recently published randomized placebo-controlled study of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) showed IVIG to be clinically effective also for this disorder in both short and long term. This survey presents data of this so-called ICE study ("Intravenous immune globulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy"). It also discusses the value of IVIG in the treatment of immune-mediated polyneuropathies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139838     DOI： 10.1007/s00115-008-2631-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  79 in total

1.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

Review 2.  Immune circuitry in the peripheral nervous system.

Authors:  Bernd C Kieseier; Hans-Peter Hartung; Heinz Wiendl
Journal:  Curr Opin Neurol       Date:  2006-10       Impact factor: 5.710

3.  Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients.

Authors:  J-M Léger; K Viala; F Cancalon; T Maisonobe; B Gruwez; T Waegemans; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-01       Impact factor: 10.154

4.  A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  N Thompson; P Choudhary; R A Hughes; R M Quinlivan
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

5.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

6.  Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Authors:  A F Hahn; C F Bolton; N Pillay; C Chalk; T Benstead; V Bril; K Shumak; M K Vandervoort; T E Feasby
Journal:  Brain       Date:  1996-08       Impact factor: 13.501

7.  Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system.

Authors:  Zsolt Illés; Michio Shimamura; Jia Newcombe; Nobuyuki Oka; Takashi Yamamura
Journal:  Int Immunol       Date:  2004-02       Impact factor: 4.823

8.  Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; F G Van der Meché; P A Van Doorn; J Meulstee; B C Jacobs; P G Oomes; R P Kleyweg; J Meulstee
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

9.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors:  M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

10.  Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barré syndrome.

Authors:  A Dilley; N A Gregson; R D M Hadden; K J Smith
Journal:  J Neuroimmunol       Date:  2003-06       Impact factor: 3.478
View more
  1 in total

1.  Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis.

Authors:  E Ece Boylu; R Erdem Toğrol; Mehmet Güney Senol; M Fatih Ozdağ; Mehmet Saraçoğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.